TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NVS

NVS

NOVARTIS AG

Next earnings Jul 21, 2026 · consensus $2.17 EPS, $14.5B rev

Sell
$159.90
▲ +1.47%
$159.90▲ +37.29%
over 1Y
L $110.15H $163.64
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.5%
1W+3.1%
1M+11.4%
3M+3.8%
YTD+18.9%
1Y+37.3%
OverviewValuationQualityFilings
Rating
Sell
Quality
A
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 34 analysts
Buy

Mixed signals in the latest filings.

NOVARTIS AG shows limited reported revenue.

On these fundamentals, NVS screens as SELL on the SEC figures.

Rule-based analysis, generated automatically from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 10:18 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$305B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-3.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
6-KPeriod ending 2026-06-112026-06-11open ↗144Filing2026-04-30open ↗6-KPeriod ending 2026-03-312026-04-28open ↗6-KPeriod ending 2026-03-182026-03-18open ↗424B5Filing2026-03-17open ↗FWPFiling2026-03-17open ↗424B5Filing2026-03-16open ↗144Filing2026-02-12open ↗144Filing2026-02-09open ↗S-8Filing2026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗6-KPeriod ending 2025-12-312026-02-04open ↗

Quality score

A
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
MomentumA
110.1552-week163.64
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is NOVARTIS AG (NVS) a buy?
NVS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
What is NOVARTIS AG's quality score?
NVS scores 86.57294787157265/100 (grade A) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001114448, latest 6-K filed 2026-06-11) · EODHD · as of 7/4/2026, 2:18:53 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2020-07-14
NOVARTIS PHARMA AG
10% owner
Acquired (C)5.91M
2020-06-30
Novartis Bioventures Ltd
Insider
Acquired (C)856K
2020-06-30
Novartis Bioventures Ltd
Insider
Acquired (C)200K
2020-06-30
Novartis Bioventures Ltd
Insider
Buy125K @ $17.00$2.13M
2020-06-19
Novartis Bioventures Ltd
Insider
Sell1.00M @ $8.25$8.26M
2020-06-18
Novartis Bioventures Ltd
Insider
Sell900.00 @ $9.04$8.14K
2020-06-17
Novartis Bioventures Ltd
10% owner
Sell4.62K @ $9.27$42.8K
2020-06-16
Novartis Bioventures Ltd
10% owner
Sell8.60K @ $9.30$80.0K
2020-06-15
Novartis Bioventures Ltd
10% owner
Sell6.16K @ $9.05$55.8K
2020-06-12
Novartis Bioventures Ltd
10% owner
Sell1.50K @ $9.19$13.8K
2020-06-11
Novartis Bioventures Ltd
10% owner
Sell7.20K @ $9.21$66.3K
2020-06-10
Novartis Bioventures Ltd
10% owner
Sell8.53K @ $9.46$80.7K

Dividends

Annual
Yield (TTM)
3.0%
Annual / share
$4.77
Last ex-date
2026-03-11
Last amount
$4.77
ex 2026-03-11paid 2026-03-16$4.77
ex 2025-03-12paid 2025-04-25$3.99
ex 2024-03-07paid 2024-04-19$3.74
ex 2023-03-09paid 2023-03-20$3.47
ex 2022-03-08paid 2022-03-17$3.36
ex 2021-03-04paid 2021-03-15$3.38

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-11-21Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-10-22Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-10-22Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2025-04-23George WhitesidesSell$100K–$250KPTR ↗
2023-08-13Daniel GoldmanSell$50.0K–$100KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Novartis (SWX:NOVN) Stock Looks Cheap on Value But Pricey After 93% ReturnBullish
finance.yahoo.com· 2026-07-03
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?Bullish
finance.yahoo.com· 2026-07-03
[Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Bullish
finance.yahoo.com· 2026-07-03
UK Cardiovascular Clinical Trials Market Projected to Reach USD 892.2 Million by 2033Bullish
globenewswire.com· 2026-07-03
Novartis gene therapy Itvisma approved in EU for spinal muscular atrophyBullish
seekingalpha.com· 2026-07-02
NVS Gains EC Approval for SMA Therapy Itvisma in Broad PopulationBullish
finance.yahoo.com· 2026-07-02

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score87 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2

News sentiment

EODHD · 47d
Bullish
+0.09
vs typical · 141 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.